vs
CATALYST PHARMACEUTICALS, INC.（CPRX）与FTAI Infrastructure Inc.（FIP）财务数据对比。点击上方公司名可切换其他公司
FTAI Infrastructure Inc.的季度营收约是CATALYST PHARMACEUTICALS, INC.的1.2倍（$188.4M vs $152.6M），CATALYST PHARMACEUTICALS, INC.净利率更高（34.5% vs -79.7%，领先114.3%），FTAI Infrastructure Inc.同比增速更快（95.9% vs 7.6%），过去两年FTAI Infrastructure Inc.的营收复合增速更高（49.0% vs 24.5%）
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
FTAI基础设施有限公司持有、运营并投资交通物流、中游能源、发电等核心领域的优质关键基础设施资产，主要面向北美市场，聚焦拥有稳定长期现金流、合同约定收入流的项目，为利益相关方创造可持续回报。
CPRX vs FIP — 直观对比
营收规模更大
FIP
是对方的1.2倍
$152.6M
营收增速更快
FIP
高出88.3%
7.6%
净利率更高
CPRX
高出114.3%
-79.7%
两年增速更快
FIP
近两年复合增速
24.5%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $152.6M | $188.4M |
| 净利润 | $52.7M | $-150.2M |
| 毛利率 | 82.9% | — |
| 营业利润率 | 40.5% | — |
| 净利率 | 34.5% | -79.7% |
| 营收同比 | 7.6% | 95.9% |
| 净利润同比 | -5.8% | -387.6% |
| 每股收益（稀释后） | $0.40 | $-1.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CPRXFIP
| Q1 26 | — | $188.4M | ||
| Q4 25 | $152.6M | $143.5M | ||
| Q3 25 | $148.4M | $140.6M | ||
| Q2 25 | $146.6M | $122.3M | ||
| Q1 25 | $141.4M | $96.2M | ||
| Q4 24 | $141.8M | $80.8M | ||
| Q3 24 | $128.7M | $83.3M | ||
| Q2 24 | $122.7M | $84.9M |
净利润CPRXFIP
| Q1 26 | — | $-150.2M | ||
| Q4 25 | $52.7M | $-97.7M | ||
| Q3 25 | $52.8M | $-104.5M | ||
| Q2 25 | $52.1M | $-70.0M | ||
| Q1 25 | $56.7M | $120.2M | ||
| Q4 24 | $55.9M | $-124.7M | ||
| Q3 24 | $43.9M | $-43.0M | ||
| Q2 24 | $40.8M | $-48.1M |
毛利率CPRXFIP
| Q1 26 | — | — | ||
| Q4 25 | 82.9% | — | ||
| Q3 25 | 84.7% | — | ||
| Q2 25 | 85.9% | — | ||
| Q1 25 | 87.3% | — | ||
| Q4 24 | 84.7% | — | ||
| Q3 24 | 85.0% | — | ||
| Q2 24 | 87.4% | — |
营业利润率CPRXFIP
| Q1 26 | — | — | ||
| Q4 25 | 40.5% | -45.7% | ||
| Q3 25 | 44.7% | -70.8% | ||
| Q2 25 | 45.2% | -56.4% | ||
| Q1 25 | 44.8% | 81.8% | ||
| Q4 24 | 44.3% | -152.7% | ||
| Q3 24 | 39.6% | -51.7% | ||
| Q2 24 | 44.2% | -56.4% |
净利率CPRXFIP
| Q1 26 | — | -79.7% | ||
| Q4 25 | 34.5% | -68.1% | ||
| Q3 25 | 35.6% | -74.4% | ||
| Q2 25 | 35.6% | -57.2% | ||
| Q1 25 | 40.1% | 125.0% | ||
| Q4 24 | 39.4% | -154.4% | ||
| Q3 24 | 34.1% | -51.6% | ||
| Q2 24 | 33.2% | -56.7% |
每股收益（稀释后）CPRXFIP
| Q1 26 | — | $-1.32 | ||
| Q4 25 | $0.40 | $-1.04 | ||
| Q3 25 | $0.42 | $-1.38 | ||
| Q2 25 | $0.41 | $-0.73 | ||
| Q1 25 | $0.45 | $0.89 | ||
| Q4 24 | $0.44 | $-1.21 | ||
| Q3 24 | $0.35 | $-0.45 | ||
| Q2 24 | $0.33 | $-0.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $709.2M | $37.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $954.3M | $-122.5K |
| 总资产 | $1.1B | $5.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CPRXFIP
| Q1 26 | — | $37.9M | ||
| Q4 25 | $709.2M | $57.4M | ||
| Q3 25 | $689.9M | $34.7M | ||
| Q2 25 | $652.8M | $33.6M | ||
| Q1 25 | $580.7M | $26.3M | ||
| Q4 24 | $517.6M | $27.8M | ||
| Q3 24 | $442.3M | $20.3M | ||
| Q2 24 | $375.7M | $33.1M |
总债务CPRXFIP
| Q1 26 | — | — | ||
| Q4 25 | — | $3.8B | ||
| Q3 25 | — | $3.7B | ||
| Q2 25 | — | $3.1B | ||
| Q1 25 | — | $2.8B | ||
| Q4 24 | — | $1.6B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.6B |
股东权益CPRXFIP
| Q1 26 | — | $-122.5K | ||
| Q4 25 | $954.3M | $21.3M | ||
| Q3 25 | $920.2M | $181.1M | ||
| Q2 25 | $856.0M | $375.5M | ||
| Q1 25 | $794.3M | $476.2M | ||
| Q4 24 | $727.6M | $202.7M | ||
| Q3 24 | $660.9M | $370.8M | ||
| Q2 24 | $608.7M | $394.8M |
总资产CPRXFIP
| Q1 26 | — | $5.7B | ||
| Q4 25 | $1.1B | $5.7B | ||
| Q3 25 | $1.1B | $5.5B | ||
| Q2 25 | $971.9M | $4.4B | ||
| Q1 25 | $908.9M | $4.1B | ||
| Q4 24 | $851.4M | $2.4B | ||
| Q3 24 | $772.0M | $2.4B | ||
| Q2 24 | $706.4M | $2.5B |
负债/权益比CPRXFIP
| Q1 26 | — | — | ||
| Q4 25 | — | 176.99× | ||
| Q3 25 | — | 20.59× | ||
| Q2 25 | — | 8.21× | ||
| Q1 25 | — | 5.79× | ||
| Q4 24 | — | 7.84× | ||
| Q3 24 | — | 4.14× | ||
| Q2 24 | — | 3.94× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.9M | $-69.4M |
| 自由现金流经营现金流 - 资本支出 | $44.9M | — |
| 自由现金流率自由现金流/营收 | 29.4% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | 0.85× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CPRXFIP
| Q1 26 | — | $-69.4M | ||
| Q4 25 | $44.9M | $-2.8M | ||
| Q3 25 | $32.4M | $-24.4M | ||
| Q2 25 | $71.3M | $-5.2M | ||
| Q1 25 | $60.0M | $-85.7M | ||
| Q4 24 | $70.9M | $-8.1M | ||
| Q3 24 | $72.9M | $14.2M | ||
| Q2 24 | $64.1M | $-17.6M |
自由现金流CPRXFIP
| Q1 26 | — | — | ||
| Q4 25 | $44.9M | $-68.6M | ||
| Q3 25 | — | $-90.7M | ||
| Q2 25 | $71.3M | $-87.5M | ||
| Q1 25 | — | $-151.7M | ||
| Q4 24 | $70.8M | $-34.3M | ||
| Q3 24 | $72.6M | $-11.7M | ||
| Q2 24 | $64.1M | $-32.1M |
自由现金流率CPRXFIP
| Q1 26 | — | — | ||
| Q4 25 | 29.4% | -47.8% | ||
| Q3 25 | — | -64.5% | ||
| Q2 25 | 48.6% | -71.6% | ||
| Q1 25 | — | -157.7% | ||
| Q4 24 | 49.9% | -42.4% | ||
| Q3 24 | 56.4% | -14.0% | ||
| Q2 24 | 52.3% | -37.9% |
资本支出强度CPRXFIP
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 45.9% | ||
| Q3 25 | 0.0% | 47.2% | ||
| Q2 25 | 0.0% | 67.3% | ||
| Q1 25 | 0.0% | 68.6% | ||
| Q4 24 | 0.1% | 32.5% | ||
| Q3 24 | 0.2% | 31.1% | ||
| Q2 24 | 0.0% | 17.2% |
现金转化率CPRXFIP
| Q1 26 | — | — | ||
| Q4 25 | 0.85× | — | ||
| Q3 25 | 0.61× | — | ||
| Q2 25 | 1.37× | — | ||
| Q1 25 | 1.06× | -0.71× | ||
| Q4 24 | 1.27× | — | ||
| Q3 24 | 1.66× | — | ||
| Q2 24 | 1.57× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
FIP
暂无分部数据
